Ge Long Hui A P P·2025-08-18 05:13Core Viewpoint - Huatai Securities reports that JD Health's total revenue for the first half of this year reached 35.29 billion yuan, representing a year-on-year increase of 24.5%, exceeding the market consensus growth expectation of 20.2% [1] Group 1: Revenue and Growth - JD Health's revenue growth is attributed to the rapid increase in traffic from JD's main platform, with daily active users (DAU) of the JD app growing by 44.8%, 33.4%, and 46.4% year-on-year from May to July 2025 according to QuestMobile [1] - The company is expected to benefit from increased advertising demand from upstream partners while enhancing its omnichannel medical service capabilities (B2C + O2O) to retain new users [1] Group 2: Profit Forecast and Valuation - Huatai Securities has raised JD Health's non-International Financial Reporting Standards (Non-IFRS) net profit forecasts for 2025 to 2027 by 26.1%, 32.5%, and 38.8%, projecting profits of 5.57 billion, 6.21 billion, and 6.9 billion yuan respectively [1] - The target price for JD Health has been adjusted from 42.1 HKD to 67.1 HKD, with a target Non-IFRS price-to-earnings ratio of 35 times for 2025, maintaining a "buy" rating [1]